Drug Search Results
More Filters [+]

CP-533,536

Alternative Names: cp-533,536, cp533,536, cp 533,536
Latest Update: 2021-04-02
Latest Update Note: PubMed Publication

Product Description

an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19250823/)

Mechanisms of Action: EP2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CP-533,536

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Tibial Fractures|Fractures, Closed

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-004183-38

P2

Completed

Unknown

2010-05-13

A3241010

P2

Completed

Tibial Fractures

2010-05-01

JapicCTI-080569

P2

Completed

Tibial Fractures|Fractures, Closed

None

Recent News Events